title: Generation of myeloma-specific T cells using dendritic cells loaded with MUC1- and hTERT- drived nonapeptides or myeloma cell apoptotic bodies.
abstract: Dendritic cells are able to induce anti-tumor immune responses by presenting tumor-specific antigens to T-lymphocytes. Various tumor-associated antigens have been studied in multiple myeloma in an effort to find a strong antigen capable of generating clinically meaningful responses in vaccinated patients. The aim of our study was to generate myeloma-specific cytotoxic T lymphocytes in vitro using dendritic cells loaded with peptide antigens or apoptotic bodies. Peripheral blood mononuclear cells from HLA-A2+ healthy donors were used for isolation and culture of dendritic cells (DCs) and T lymphocytes. DCs were loaded with hTERT- and MUC1-derived nonapeptides or apoptotic bodies from myeloma cells. Repeated stimulation of T lymphocytes led to their activation characterized by interferon-gamma production. Activated T lymphocytes were separated immunomagnetically and expanded in vitro. Specific cytotoxicity of the expanded T lymphocytes was tested against a myeloma cell line. There was evidence of cytotoxicity for all three types of antigens used for T lymphocyte priming and expansion. No statistically significant differences were observed in T lymphocyte cytotoxicity for any of the antigens. We present a method for the priming and expansion of myeloma-specific T lymphocytes using dendritic cells loaded with different types of tumor antigens. Cytotoxic T lymphocytes and/or activated dendritic cells generated by the described methods can be applied for cellular immunotherapy against multiple myeloma and other malignancies.
authors.affiliation: University Cell Immunotherapy Center, Masaryk University, Brno, Czech Republic.
authors.forename: D
authors.initials: D
authors.lastname: Ocadlikova
authors.forename: F
authors.initials: F
authors.lastname: Kryukov
authors.forename: K
authors.initials: K
authors.lastname: Mollova
authors.forename: L
authors.initials: L
authors.lastname: Kovarova
authors.forename: I
authors.initials: I
authors.lastname: Buresdova
authors.forename: E
authors.initials: E
authors.lastname: Matejkova
authors.forename: M
authors.initials: M
authors.lastname: Penka
authors.forename: T
authors.initials: T
authors.lastname: Buchler
authors.forename: R
authors.initials: R
authors.lastname: Hajek
authors.forename: J
authors.initials: J
authors.lastname: Michalek
mesh_terms: D017209:Apoptosis; D002478:Cells, Cultured; D003713:Dendritic Cells / Q000276:immunology*; D006801:Humans; D016219:Immunotherapy, Adoptive; D007371:Interferon-gamma / Q000096:biosynthesis; D008213:Lymphocyte Activation; D018396:Mucin-1 / Q000276:immunology*; D009101:Multiple Myeloma / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D010446:Peptide Fragments / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D019098:Telomerase / Q000276:immunology*
chemical_list: C060192:MUC1 protein, human; D018396:Mucin-1; D010446:Peptide Fragments; D007371:Interferon-gamma; C509186:TERT protein, human; D019098:Telomerase